Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CN008-0003  |   NCT06268886

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Summary

  • Phase 2
  • Male and Female Gender icon
  • 50-80
    Age Range
  • 153
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) core clinical criteria.
    1. Global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and a CDR-Memory Box score of 0.5 and greater at screening and Baseline.
      1. Evidence of AD pathology.
        1. Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory Subtest II (WMS-IV LM II).
          1. Mini Mental Status Examination (MMSE) score ≥ 22 to 30 (inclusive).

            Exclusion Criteria

            Exclusion Criteria Icon
            • Any evidence of a condition that may affect cognition other than AD.
              1. Contraindications to PET imaging.
                1. Inability to tolerate or contraindication to magnetic resonance imaging.
                  1. Any serious medical condition that could, in the opinion of the investigator, affect the participant's safety or interfere with study assessments.
                    1. Geriatric Depression Scale (GDS) score greater than or equal to 8 at screening.
                      Additional Information *
                      • Other protocol-defined Inclusion/Exclusion criteria apply.

                        Treatment Options

                        Study Arms

                        ASSIGNED INTERVENTION

                        Study Arms

                        Experimental: BMS-986446 Dose A

                        ASSIGNED INTERVENTION
                        • Drug: BMS-986446

                        Study Arms

                        Experimental: BMS-986446 Dose B

                        ASSIGNED INTERVENTION
                        • Drug: BMS-986446

                        Study Arms

                        Placebo Comparator: Placebo

                        ASSIGNED INTERVENTION
                        • Other: Placebo
                        Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                        Check Your Eligibility
                        Answer some questions about Your health to see if you may match to this trial
                        Match to a Trial
                        If you are a match, click on the study to see the list of study site locations
                        Select a Study Site Location
                        Select a study site location that is convenient for you
                        Register
                        Provide your contact details for the study site to connect with you.

                        Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you